U.S. markets close in 5 hours 34 minutes
  • S&P 500

    3,460.12
    +17.00 (+0.49%)
     
  • Dow 30

    28,424.85
    +116.06 (+0.41%)
     
  • Nasdaq

    11,585.91
    +69.41 (+0.60%)
     
  • Russell 2000

    1,620.86
    +3.15 (+0.19%)
     
  • Crude Oil

    41.08
    -0.62 (-1.49%)
     
  • Gold

    1,931.60
    +16.20 (+0.85%)
     
  • Silver

    25.30
    +0.32 (+1.28%)
     
  • EUR/USD

    1.1874
    +0.0045 (+0.38%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • GBP/USD

    1.3141
    +0.0194 (+1.50%)
     
  • USD/JPY

    104.4960
    -0.9740 (-0.92%)
     
  • BTC-USD

    12,607.65
    +1,550.64 (+14.02%)
     
  • CMC Crypto 200

    250.68
    +5.79 (+2.36%)
     
  • FTSE 100

    5,811.71
    -77.51 (-1.32%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Need To Know: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Insiders Have Been Buying Shares

Simply Wall St

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might well want to know whether insiders have been buying or selling shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST).

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, most countries require that the company discloses such transactions to the market.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.'

See our latest analysis for Aquestive Therapeutics

Aquestive Therapeutics Insider Transactions Over The Last Year

Senior VP & CFO John Maxwell made the biggest insider purchase in the last 12 months. That single transaction was for US$98k worth of shares at a price of US$9.80 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$5.60). It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

Over the last year, we can see that insiders have bought 32095 shares worth US$308k. While Aquestive Therapeutics insiders bought shares last year, they didn't sell. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGM:AQST Recent Insider Trading, April 26th 2019
NasdaqGM:AQST Recent Insider Trading, April 26th 2019

Aquestive Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Aquestive Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Aquestive Therapeutics insiders own 14% of the company, worth about US$19m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Aquestive Therapeutics Insiders?

The fact that there have been no Aquestive Therapeutics insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in Aquestive Therapeutics and we see no evidence to suggest they are worried about the future. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

Of course Aquestive Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.